Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In several recent studies, we have shown that P-LAP can be a poor prognostic factor and a factor of chemoresistance in endometrial carcinoma, especially in the advanced patients. In our study, we investigated whether P-LAP alters the expression of apoptosis regulatory proteins as a mechanism of drug resistance. We transfected P-LAP cDNA into A-MEC cells (endometrial adenocarcinoma cell line), and A-MEC-LAP cells displayed a 1.8-fold, 2.0-fold and 1.7-fold increase in IC(50) against paclitaxel, carboplatin and cisplatin respectively. Translational downregulation by siRNA2 to P-LAP on A-MEC-LAP cells demonstrated 60%, 51% and 58% decrease in IC(50). To investigate the mechanism of P-LAP-induced chemoresistance, we also assessed whether P-LAP transfection had an effect on carboplatin-induced apoptotic death of A-MEC cells. A-MEC and A-MEC-pc (transfected with vector alone) cells exhibited a strong apoptotic response to carboplatin, while A-MEC-LAP cells exhibited a weak apoptotic response. In an attempt to identify the mechanism of the inhibitory effect on apoptotic response to carboplatin, we next assessed the expression of cleaved caspases and PARP cleavage. While treatment of A-MEC-pc cells with carboplatin exhibited increased levels of cleaved caspase 3, caspase 7 and caspase 9 compared to that after no treatment, A-MEC-LAP cells did not show any expression of these caspases. These results suggest that P-LAP reduces sensitivity to anticancer drugs via inhibition of mitochondria-mediated apoptosis, and may be a molecular target for conquering anticancer drug resistance.
 ...
PMID:A novel role for placental leucine aminopeptidase (P-LAP) as a determinant of chemoresistance in endometrial carcinoma cells. 1618 79

The role of minimally invasive surgery in the management of gynecologic cancers continues to expand. Radical vaginal trachelectomy with laparoscopic pelvic lymphadenectomy has emerged as a safe, reasonable option for women with early-stage cervical cancer desiring fertility preservation. Similarly, laparoscopically assisted radical vaginal hysterectomy has been systematically described, is feasible, and can be offered to women with early-stage cervical cancer who do not desire future childbearing. In the treatment of early-stage endometrial cancer, the surgical approach of laparoscopic hysterectomy, peritoneal washings, and pelvic and para-aortic lymph node dissection, with or without an omentectomy, is being compared with the same surgery performed via laparotomy in the cooperative Gynecologic Oncology Group LAP 2 study, which has completed accrual, and appears to be a reasonable surgical option. In ovarian cancer, minimally invasive surgery has been incorporated to manage early-stage, advanced-stage, and recurrent disease, as well as second-look procedures. Hand-assisted laparoscopy has also recently been described in managing larger volume primary and recurrent gynecologic cancers. Extraperitoneal laparoscopy for para-aortic and pelvic lymph node dissections has been shown to yield adequate nodal counts and to be safe and feasible in the management of gynecologic cancers.
 ...
PMID:Role of minimally invasive surgery in gynecologic cancers. 1695 93

The laparoscopic management of gynecologic cancers has been discussed controversely since decades. Much progress has been achieved technically enabling an experienced endoscopic surgeon to perform most of the gynecologic oncologic procedures such as hysterectomy, omentectomy, pelvic and paraaortic lymph node dissection. Although the value of laparoscopy with respect to oncological safety and patient's outcome has not been shown in prospective randomized clinical trials, many studies with altogether thousands of patients have revealed the feasibility and also similar oncologic results of laparoscopy when compared to laparotomy. Therefore, the laparoscopic approach has become well accepted for certain oncological indications, especially when early stage cancer cases are treated. These indications are also subject to ongoing Phase III trials: The LACC001 trial compares Total Laparoscopic Radical Hysterectomy (TLRH) or total robotic radical hysterectomy with total abdominal radical hysterectomy (TARH) for the treatment of early stage cervical cancer. The GOG LAP 2 and also the LACE001 trial compare total laparoscopic hysterectomy (TLH) with total abdominal hysterectomy (TAH) for the treatment of early stage endometrial cancer, whereby bilateral salpingo-oophorectomy, pelvic and paraaortic lymph node dissection is performed according to tumor stage and grade. This review summarizes the current status of laparoscopy in gynecologic oncology based on the literature to date, the ongoing clinical trials, and the recommendations of the German Gynecologic Oncology Group (AGO).
 ...
PMID:The value of laparoscopic surgery to stage gynecological cancers: present and future. 1974 97